Abstract
Shock, particularly septic shock, remains a critical medical condition with high mortality rates due to inadequate blood flow and subsequent multi-organ failure. This prospective observational study evaluated the rationale use of noradrenaline and vasopressin in 50 critically ill patients. Septic shock was the most prevalent diagnosis (68%), primarily driven by lower respiratory tract infections and urosepsis. Results indicated significant improvements in blood pressure, particularly diastolic pressure when vasopressin was used. Furthermore, significant reductions in serum lactate, C-reactive protein (CRP), and troponin were observed, suggesting improved tissue perfusion and reduced systemic inflammation without significant adverse drug interactions.
Introduction
Shock is a life-threatening condition where insufficient blood flow leads to cellular dysfunction and organ failure. Septic shock, the most severe form, carries a staggering mortality rate of 50-75%. While fluid resuscitation and antibiotics are foundational treatments, vasopressors like noradrenaline (norepinephrine) and vasopressin are essential for maintaining hemodynamic stability. This study aims to evaluate the clinical application and efficacy of these vasopressors in a real-world tertiary care setting, focusing on their impact on blood pressure and biochemical markers of physiological stress.
Methods
This prospective observational study was conducted at a tertiary care hospital from January to October 2023. The cohort included 50 critically ill patients admitted to the ICU, HICU, or CCU diagnosed with septic, cardiogenic, or hypovolemic shock. Patients were treated with noradrenaline, vasopressin, or a combination of both. Exclusion criteria included pregnancy, breastfeeding, and patients undergoing dialysis. Data collection encompassed demographics, drug dosages, treatment duration, and laboratory parameters including arterial blood gas (ABG), serum lactate, CRP, troponin, and potassium levels.
Results
The study population was 58% male and 42% female, with the 61-70 age group being the most represented (24%). Septic shock was the dominant diagnosis, accounting for 68% of cases.
Lower respiratory tract infections (LRTI) were the leading cause of shock (23.4%), followed by urosepsis (19.14%). Hemodynamic monitoring revealed distinct trends for each vasopressor. Patients receiving noradrenaline reached a mean systolic blood pressure of approximately 110 mmHg by day six. Those on vasopressin experienced a steady rise in diastolic blood pressure, increasing from an initial 63.20 mmHg to 70 mmHg by day five.
The overall patient outcome was positive for the majority, with 62% of patients being discharged following clinical improvement. However, the severity of the underlying conditions resulted in a 24% mortality rate.
Discussion
The findings highlight the efficacy of norepinephrine as a primary vasopressor and the potential benefits of combination therapy. The 16% of patients who received both norepinephrine and vasopressin showed more stable and prominent increases in diastolic blood pressure, suggesting a synergistic hemodynamic effect.
Crucially, the study observed significant decreases in serum lactate, C-reactive protein (CRP), and troponin levels. These biochemical shifts indicate that the vasopressor therapy successfully addressed the underlying pathophysiology by improving tissue oxygenation and reducing systemic inflammation and cardiac strain. Safety was also a key finding; no significant fluctuations in potassium levels or adverse drug interactions were noted, supporting the standard clinical use of these agents.
Conclusion
This study demonstrates that the rational use of noradrenaline and vasopressin significantly improves hemodynamic parameters in critically ill patients with shock. The observed reduction in inflammatory and cardiac biomarkers underscores the systemic benefits of effective vasopressor therapy. While limited by a small sample size and single-center design, these results provide a foundation for larger multi-center trials to further refine therapeutic strategies for shock management.
Summary updated